First oncolytic virus approved for melanoma immunotherapy. Academic Article uri icon

Overview

abstract

  • On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

publication date

  • December 8, 2015

Identity

PubMed Central ID

  • PMC4760283

Scopus Document Identifier

  • 84956607773

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2015.10.012

PubMed ID

  • 26942095

Additional Document Info

volume

  • 5

issue

  • 1